Literature DB >> 33841593

Implication of heart rate optimization in patients with heart failure.

Masakazu Hori1, Teruhiko Imamura1, Koichiro Kinugawa1.   

Abstract

Prognostic impact of heart rate reduction therapy using ivabradine, a selective inhibitor of If channel that purely reduces heart rate, in patients with heart failure with reduced ejection fraction and sinus tachycardia has been demonstrated. However, ideal heart rate remains unknown. We experienced an 80-year-old woman with reduced left ventricular ejection fraction who was hospitalized due to congestive heart failure. Following the ivabradine administration that decreased her heart rate from 100 bpm down to around 60 bpm, the "overlap" between E-wave and A-wave in the trans-mitral Doppler echocardiography diminished, accompanied by an improvement in cardiac output. Heart rate optimization targeting to diminish the overlap between E-wave and A-wave might maximize cardiac output and improve the clinical course via facilitated cardiac reverse remodeling. Further studies are warranted to validate the implication of therapeutic strategy to aggressively minimize the echocardiographic "overlap" by heart rate reduction therapy in heart failure patients.
© 2020 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Case report; Deceleration time; Heart failure; Hemodynamics

Year:  2020        PMID: 33841593      PMCID: PMC8020069          DOI: 10.1016/j.jccase.2020.11.016

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  7 in total

1.  Histopathological and Immunological Characteristics of Tachycardia-Induced Cardiomyopathy.

Authors:  Karin A L Mueller; David Heinzmann; Karin Klingel; Petra Fallier-Becker; Reinhard Kandolf; Antonios Kilias; Britta Walker-Allgaier; Oliver Borst; Jörg Kumbrink; Thomas Kirchner; Harald Langer; Tobias Geisler; Jürgen Schreieck; Michael Gramlich; Meinrad Gawaz; Peter Seizer
Journal:  J Am Coll Cardiol       Date:  2017-05-02       Impact factor: 24.094

2.  Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure - J-SHIFT Study.

Authors:  Hiroyuki Tsutsui; Shin-Ichi Momomura; Akira Yamashina; Hiroaki Shimokawa; Yasuki Kihara; Yoshihiko Saito; Nobuhisa Hagiwara; Hiroshi Ito; Masafumi Yano; Kazuhiro Yamamoto; Junya Ako; Takayuki Inomata; Yasushi Sakata; Takashi Tanaka; Yasushi Kawasaki
Journal:  Circ J       Date:  2019-08-08       Impact factor: 2.993

3.  Measurement of cardiac output with non-invasive Aesculon impedance versus thermodilution.

Authors:  Hedelin Petter; Agger Erik; Ekmehag Björn; Rådegran Göran
Journal:  Clin Physiol Funct Imaging       Date:  2010-09-23       Impact factor: 2.273

4.  Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.

Authors:  Michael Böhm; Karl Swedberg; Michel Komajda; Jeffrey S Borer; Ian Ford; Ariane Dubost-Brama; Guy Lerebours; Luigi Tavazzi
Journal:  Lancet       Date:  2010-09-11       Impact factor: 79.321

5.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Authors:  Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Ariane Dubost-Brama; Guy Lerebours; Luigi Tavazzi
Journal:  Lancet       Date:  2010-09-11       Impact factor: 79.321

Review 6.  Novel rate control strategy with landiolol in patients with cardiac dysfunction and atrial fibrillation.

Authors:  Teruhiko Imamura; Koichiro Kinugawa
Journal:  ESC Heart Fail       Date:  2020-07-14

7.  How to consider target heart rate in patients with systolic heart failure.

Authors:  Toshihide Izumida; Teruhiko Imamura; Makiko Nakamura; Nobuyuki Fukuda; Koichiro Kinugawa
Journal:  ESC Heart Fail       Date:  2020-06-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.